FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097661119> ?p ?o ?g. }

• W2097661119 endingPage "1141" @default.
• W2097661119 startingPage "1135" @default.
• W2097661119 abstract "Purpose Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses protein kinase C (PKC) and protein kinase B/AK transforming (AKT) signaling, induces tumor cell apoptosis, and inhibits proliferation and angiogenesis. Increased PKC and AKT activity is associated with poor prognosis in non–small-cell lung cancer (NSCLC). This phase II trial of enzastaurin was conducted to determine the 6-month progression-free survival (PFS) rate in advanced, metastatic NSCLC. Patients and Methods Patients with metastatic (stage IV and wet IIIB) NSCLC, Eastern Cooperative Oncology Group performance status ≤ 2, and ≤ two prior systemic regimens (including one or more platinum-based chemotherapy regimens) received 500 mg of enzastaurin administered once daily. Results Fifty-five patients were enrolled (55% male patients, 45% female patients; median age, 63 years; range, 44 to 82 years; 78% of patients having stage IV disease). Adenocarcinoma was the most common diagnosis (65%). Prior therapies included radiotherapy (73%) and epidermal growth factor inhibitors (29%). Median PFS was 1.8 months (95% CI, 1.7 to 1.9). Six-month PFS rate was 13% (95% CI, 3.9% to 21.5%). Median overall survival (OS) was 8.4 months (95% CI, 6.0 to 13.6 months). The 12-month OS rate was 44% (95% CI, 30.5% to 57.3%). Nineteen patients (35%) had stable disease. No objective responses were observed. Seven patients (13%) had PFS ≥ 6 months, three of whom continued for more than 10 months. The most common toxicity was fatigue (grade ≤ 3; n = 17). Grade 3 or worse toxicities were fatigue (n = 2), thromboembolism (n = 1), ataxia (n = 1), and anemia (n = 1). Two patients discontinued treatment because of drug-related fatigue and dizziness. Five patients died while enrolled in the study (non drug-related). Conclusion Although the primary end point of a 20% PFS rate was not achieved, 13% of the patients had PFS for ≥ 6 months. Given the tolerability and survival data, evaluation of enzastaurin in combination with cytotoxic drugs is warranted in NSCLC." @default.
• W2097661119 created "2016-06-24" @default.
• W2097661119 creator A5001557696 @default.
• W2097661119 creator A5008593691 @default.
• W2097661119 creator A5020867061 @default.
• W2097661119 creator A5022619396 @default.
• W2097661119 creator A5033549340 @default.
• W2097661119 creator A5064692327 @default.
• W2097661119 creator A5072308451 @default.
• W2097661119 date "2008-03-01" @default.
• W2097661119 modified "2023-10-12" @default.
• W2097661119 title "Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non–Small-Cell Lung Cancer" @default.
• W2097661119 cites W1839238860 @default.
• W2097661119 cites W1978265027 @default.
• W2097661119 cites W1986099901 @default.
• W2097661119 cites W1995236496 @default.
• W2097661119 cites W2005216767 @default.
• W2097661119 cites W2007359720 @default.
• W2097661119 cites W2007901011 @default.
• W2097661119 cites W2010397777 @default.
• W2097661119 cites W2022212375 @default.
• W2097661119 cites W2022514267 @default.
• W2097661119 cites W2023898364 @default.
• W2097661119 cites W2037139573 @default.
• W2097661119 cites W2044483989 @default.
• W2097661119 cites W2070819486 @default.
• W2097661119 cites W2081598827 @default.
• W2097661119 cites W2082801302 @default.
• W2097661119 cites W2087933507 @default.
• W2097661119 cites W2094047942 @default.
• W2097661119 cites W2097449310 @default.
• W2097661119 cites W2108193919 @default.
• W2097661119 cites W2110835998 @default.
• W2097661119 cites W2120718661 @default.
• W2097661119 cites W2126372596 @default.
• W2097661119 cites W2130652363 @default.
• W2097661119 cites W2134667653 @default.
• W2097661119 cites W2138297714 @default.
• W2097661119 cites W2139248078 @default.
• W2097661119 cites W2139377071 @default.
• W2097661119 cites W2142383042 @default.
• W2097661119 cites W2145835533 @default.
• W2097661119 cites W2146404049 @default.
• W2097661119 cites W2158713283 @default.
• W2097661119 cites W2162724777 @default.
• W2097661119 cites W2167236214 @default.
• W2097661119 cites W2170655985 @default.
• W2097661119 cites W2172187886 @default.
• W2097661119 cites W2227340362 @default.
• W2097661119 cites W2233933972 @default.
• W2097661119 cites W2247225824 @default.
• W2097661119 cites W2299836454 @default.
• W2097661119 cites W2339026282 @default.
• W2097661119 cites W2584142366 @default.
• W2097661119 doi "https://doi.org/10.1200/jco.2007.14.3685" @default.
• W2097661119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18309949" @default.
• W2097661119 hasPublicationYear "2008" @default.
• W2097661119 type Work @default.
• W2097661119 sameAs 2097661119 @default.
• W2097661119 citedByCount "60" @default.
• W2097661119 countsByYear W20976611192012 @default.
• W2097661119 countsByYear W20976611192013 @default.
• W2097661119 countsByYear W20976611192014 @default.
• W2097661119 countsByYear W20976611192015 @default.
• W2097661119 countsByYear W20976611192017 @default.
• W2097661119 countsByYear W20976611192018 @default.
• W2097661119 countsByYear W20976611192019 @default.
• W2097661119 countsByYear W20976611192020 @default.
• W2097661119 countsByYear W20976611192021 @default.
• W2097661119 crossrefType "journal-article" @default.
• W2097661119 hasAuthorship W2097661119A5001557696 @default.
• W2097661119 hasAuthorship W2097661119A5008593691 @default.
• W2097661119 hasAuthorship W2097661119A5020867061 @default.
• W2097661119 hasAuthorship W2097661119A5022619396 @default.
• W2097661119 hasAuthorship W2097661119A5033549340 @default.
• W2097661119 hasAuthorship W2097661119A5064692327 @default.
• W2097661119 hasAuthorship W2097661119A5072308451 @default.
• W2097661119 hasBestOaLocation W20976611191 @default.
• W2097661119 hasConcept C121608353 @default.
• W2097661119 hasConcept C126322002 @default.
• W2097661119 hasConcept C143998085 @default.
• W2097661119 hasConcept C185592680 @default.
• W2097661119 hasConcept C190283241 @default.
• W2097661119 hasConcept C2776256026 @default.
• W2097661119 hasConcept C2776694085 @default.
• W2097661119 hasConcept C55493867 @default.
• W2097661119 hasConcept C71924100 @default.
• W2097661119 hasConcept C75217442 @default.
• W2097661119 hasConcept C90924648 @default.
• W2097661119 hasConceptScore W2097661119C121608353 @default.
• W2097661119 hasConceptScore W2097661119C126322002 @default.
• W2097661119 hasConceptScore W2097661119C143998085 @default.
• W2097661119 hasConceptScore W2097661119C185592680 @default.
• W2097661119 hasConceptScore W2097661119C190283241 @default.
• W2097661119 hasConceptScore W2097661119C2776256026 @default.
• W2097661119 hasConceptScore W2097661119C2776694085 @default.
• W2097661119 hasConceptScore W2097661119C55493867 @default.
• W2097661119 hasConceptScore W2097661119C71924100 @default.

• next